An Abdominal Mass in an Infant: Neuroblastoma and Its Markers

Medically reviewed by Dr. Michael Kachur · Frankfurt, Germany·

It usually starts with a hand. A nappy change, a bath, and a parent's fingers find something firm and deep on one side of a baby's belly. The hard part is that the first real question is not what this is but how fast that has to be answered, and the answer gets assembled out of an age, a scan, a urine result and a genomic report. Holding those four as one case from the first week is what Healz is for.

Category
Health Insights
Date
Reading time
11 min
Share

This post is about neuroblastoma and what each piece of the workup is for. Most firm bellies in babies are not this.

An Abdominal Mass in an Infant: Neuroblastoma and Its Markers

What a firm belly in a baby usually turns out to be

Neuroblastoma is the most common extracranial solid tumour in childhood, and the NCI PDQ health professional summary counts more than 650 cases a year in the United States. It starts where the sympathetic nervous system is: that summary says it originates in the adrenal medulla and paraspinal or periaortic regions where sympathetic nervous system tissue is present. A review by Papaioannou and McHugh in Cancer Imaging (2005) describes these tumours as deriving from primordial neural crest cells, the precursors of the sympathetic nervous system.

The ages are narrow. Per the PDQ health professional summary, about 37% of patients are diagnosed as infants and 90% are younger than 5 years, with a median age at diagnosis of 17 months, and it says the highest rate of diagnosis is in the first month of life. An abdominal mass is listed as the most common presentation.

Ask Healz.

One chat instead of ten apps. 1M+ rare cases checked. The root cause, not the label. Private.

Our piece on a liver mass in a young child and the AFP result covers a different organ and a different protein, read against the child's age.

The signs that point somewhere other than the abdomen

Many presentations have nothing to do with a lump. The PDQ health professional summary lists them:

  • Bone pain, in association with metastatic disease, which in a small child reads as a limp.
  • Proptosis and periorbital ecchymosis, common in high-risk patients, arising from retrobulbar metastasis.
  • Fever, hypertension and anaemia, occasionally found in patients without metastasis.
  • Paralysis. Tumour from paraspinal ganglia may invade through neural foramina and compress the spinal cord extradurally, and immediate treatment is given for symptomatic cord compression.
  • Watery diarrhoea, caused on rare occasions by secretion of vasoactive intestinal peptide by the tumour, which can be the first symptom.
  • Horner syndrome, miosis with ptosis and anhidrosis, from a tumour in the stellate ganglion.
  • Subcutaneous skin nodules, often with a bluish discolouration of the overlying skin, usually seen only in infants.

Opsoclonus and myoclonus, the jerking eye and limb movements, occur rarely in neuroblastoma, but the summary reports that about half of children presenting with opsoclonus and myoclonus syndrome are found to have neuroblastoma. The hypertension belongs to the tumour's own chemistry, the catecholamine pathway that also runs behind episodic hypertension from a phaeochromocytoma.

What the markers and the scans are each for

The markers are the tumour's chemistry in the urine. Per the PDQ health professional summary, urinary excretion of the catecholamine metabolites VMA and HVA per milligram of excreted creatinine is measured before therapy, a 24-hour collection is not needed, and if they stay elevated the markers can suggest the persistence of disease. Serum catecholamines, the same summary says, are not routinely used in the diagnosis.

Papaioannou and McHugh write that ultrasonography is the initial imaging modality to investigate a child or an infant with a palpable abdominal mass, and in a baby it needs no sedation. Their review also carries the detail that separates this from a kidney tumour on the first pass: coarse, finely stippled or curvilinear calcifications are seen in 85% of abdominal neuroblastomas on CT, and the ipsilateral kidney is usually displaced by the large retroperitoneal tumour, whose identification facilitates differentiation from Wilms tumour.

Then ultrasound stops being enough. The PDQ health professional summary says three-dimensional imaging of the primary tumour and its lymph node drainage sites is done with CT and/or MRI of the chest, abdomen and pelvis, because ultrasonography is generally considered suboptimal for accurate three-dimensional measurements. MRI of the spine adjacent to any paraspinal tumour is part of staging, because of the foramina. The cross-sectional study is where the image-defined risk factors are read, which in the International Neuroblastoma Risk Group Staging System (INRGSS) categorise locoregional tumours as L1 when they are absent and L2 when present. MIBG scanning is a critical part of the standard diagnostic evaluation, for the primary tumour, for sites of metastases and for assessing response. Marrow is assessed by bilateral iliac crest aspirates and trephine core biopsies.

The one cancer diagnosis that can be made without the tumour

This is a formal international rule, not a shortcut. The PDQ health professional summary states that the minimum criterion for a diagnosis of neuroblastoma, as established by international agreement, is that the diagnosis must be based on one of the following: an unequivocal pathological diagnosis made from tumour tissue by light microscopy, with or without immunohistology or electron microscopy; or the combination of a bone marrow aspirate or trephine biopsy containing unequivocal tumour cells, for example syncytia or immunocytologically positive clumps of cells, and increased levels of urinary catecholamine metabolites.

It comes with limits. In patients older than 18 months with INSS stage 4 disease, the summary says extensive marrow involvement plus elevated catecholamine metabolites may be adequate for diagnosis and risk assignment, but the International Neuroblastoma Pathology Classification cannot be determined from tumour metastatic to bone marrow, so every attempt should be made to biopsy the primary tumour.

Why the whole workup exists: the risk group

All of it is collected to decide which risk group this child is in, because the treatment follows the group. The PDQ health professional summary describes the International Neuroblastoma Risk Group classification as assigning patients to one of 16 pretreatment risk groups based on INRG stage, age, histological category, grade of tumour differentiation, MYCN amplification, 11q aberration (the only segmental chromosomal aberration studied) and ploidy.

One factor outweighs the rest. MYCN amplification is detected in 16% to 25% of neuroblastoma tumours and in 40% to 50% of high-risk cases, and in the INRG classification table that summary reproduces, every row with amplified MYCN lands in a high-risk group. The clinical version is stated directly: patients most at risk for disease progression and mortality are older than 18 months, have metastatic disease or localised disease with unfavourable biology such as MYCN amplification, or have unfavourable histology. Even the most favourable-looking infant pattern is not exempt: roughly 8% to 10% of infants with INRGSS stage MS disease have MYCN-amplified tumours and are usually treated using high-risk protocols. Chromosome 11q loss occurs in approximately 30% of high-risk cases.

The subset that gets better without being treated

The PDQ health professional summary says spontaneous regression has been described in infants, especially in those with the INSS 4S and INRGSS MS pattern of metastatic spread. On management it goes further: a COG study determined that selected small INSS stage 1 or stage 2 adrenal masses, presumed to be neuroblastoma, detected in infants younger than 6 months by screening or incidental ultrasonography may safely be observed without obtaining a definitive histological diagnosis and without surgical intervention, and the same summary reports expectant observation is safe in patients younger than 6 months with solid adrenal tumours smaller than 3.1 cm, or cystic tumours smaller than 5 cm, and INSS stage 1 disease.

How common that is came out of trying to screen for it. The same summary reports that in screening trials in Quebec and Germany the incidence of neuroblastoma was twice that reported in non-screened populations, suggesting many neuroblastomas are never diagnosed clinically and spontaneously regress. The NCI PDQ neuroblastoma screening summary is blunt: based on solid evidence, screening infants for neuroblastoma results in overdiagnosis, there is no evidence from controlled studies or randomised trials of decreases in mortality, and the Japanese programme that began in the mid-1980s was halted in 2003.

So treatment runs from nothing to almost everything. At one end, the summary says surgery alone, even without complete resection, can cure nearly all patients with INSS stage 1 neuroblastoma. At the other, high-risk treatment comes in three phases: induction, with chemotherapy and surgical resection; consolidation, with tandem cycles of myeloablative therapy and stem cell transplant plus radiation; and postconsolidation immunotherapy with GM-CSF and isotretinoin, where anti-GD2 antibodies are often used. None of it ends at discharge: survivors require close monitoring because cancer therapy side effects may persist or develop months or years after treatment.

How Healz assembles the risk group out of four arrivals

In this one disease the answer can be to watch rather than to treat, so the risk group has to be assembled out of an age, a scan, a marker level and a genomic result before anyone knows which path the child is on. Those four reach a family separately, and Healz keeps them in one chat instead of ten apps.

Healz is equipped with Frontier AI, so a cancer ai works the whole case rather than the newest page in it: the ultrasound wording beside the cross-sectional report that followed it, each HVA and VMA value beside its date, the marrow or pathology result beside the MYCN finding.

Healz is equipped with root-cause technology, so it does not stop at the first label. It asks the questions a rushed appointment skips and cross-checks the case against more than a million rare cases, which is how a benign or non-renal alternative stays on the list until the tissue or the markers remove it.

Healz's memory pulls the medical facts out of every upload, keeps abnormal values up front and dates them, so the catecholamine series, the scan measurements and the genomic report sit in one timeline with the child's age attached to each. A second opinion is then fast to ask for, because the case does not have to be rebuilt first. You can bring a board-certified doctor into the same chat for a second opinion.

Frequently asked questions

Is a lump in my baby's belly always cancer?

No. Most abdominal masses found in infants are not neuroblastoma, and several possibilities are benign. A firm, deep mass does prompt imaging, and per Papaioannou and McHugh ultrasonography is the first imaging test for a child or infant with a palpable abdominal mass.

What do the HVA and VMA urine tests look for?

They measure the breakdown products of the catecholamines this tumour tissue makes. Per the NCI PDQ health professional summary they are measured per milligram of excreted creatinine before therapy, no 24-hour collection is needed, and levels that stay high can suggest that disease persists.

What does MYCN amplification mean in neuroblastoma?

Extra copies of one gene in the tumour, and it is the genomic finding that carries the most weight. Per the NCI PDQ health professional summary it is detected in 16% to 25% of neuroblastoma tumours, and in the INRG classification table every row with amplified MYCN sits in a high-risk group.

Can neuroblastoma go away on its own?

In a specific subset, yes. The NCI PDQ health professional summary says spontaneous regression has been described in infants, especially with the INSS 4S and INRGSS MS pattern, and that in infants younger than 6 months a small INSS stage 1 or stage 2 adrenal mass may safely be observed without surgery or a tissue diagnosis, with expectant observation reported safe for solid adrenal tumours smaller than 3.1 cm, or cystic tumours smaller than 5 cm, in INSS stage 1 disease. The screening summary says screening infants results in overdiagnosis.

It usually starts with a hand, and what follows is four results that only mean something once someone has put them in one place with the baby's age beside them.

Written by Healz Team · Filed under Health Insights

Your health deserves more than guesswork

Get a real investigation, not a symptom list. Root causes found, history remembered, dots connected.

Not a medical provider. Healz.ai is an educational service. Always discuss every decision with your doctor. AI can make mistakes.

© 2026 HealzAI Inc1111B S Governors Ave #92123, Dover, DE 19904, USAMade with for better health